Our team is comprised of scientists from across Canada 🇨🇦, spanning multiple disciplines. Pictured here: our rare disease registry team meeting in Halifax. It was such a valuable opportunity to connect in person. Moments like this remind us how powerful national collaboration is!

Pregnant patients with rheumatic diseases face higher preeclampsia risk. In our study from a Canadian registry, most met criteria for low-dose aspirin (ASA). While outcomes were similar between groups, findings support low-dose aspirin use in high-risk patients per guidelines. #Rheumatology #OBGYN

PhD student Nicole Andersen & scientist Dr. Deborah Da Costa presenting their study that looked at cannabis use in people with inflammatory arthritis enrolled in testing an intervention for insomnia. 🔑Key findings in ⬇️ reply.

Pictured here is Arthritis Research Canada scientist Dr. May Choi and her team at the 2026 CRA Annual Scientific Meeting!

We are excited to share executive summaries of the research abstracts that Arthritis Research Canada scientists & trainees are presenting at the 2026 Canadian Rheumatology Association Scientific Meeting. Check out our presentations here: ow.ly/9ckM50YKJiJ

Congratulations to Dr. Raheem Kherani for being recognized with a Practice Reflection Award from the Canadian Rheumatology Association for leading the development of a mini practice audit tool with UBC rheumatology resident Dr. Madelaine Beckett that allows rheumatologists to review & improve care!

Our Scientific Director Dr. @dlacaille.bsky.social & scientist Dr. Cheryl Barnabe are at the 2026 CRA Annual Scientific Meeting in Halifax this week. Dr. Cheryl Barnabe was honoured with a Distinguished Investigator award for her research & work providing arthritis care in Indigenous communities.

Our new study finds HCQ retinopathy risk increases with duration and dose. Pooled prevalence is 5.1%, and cumulative incidence reaches 5.6% by 15 years. Higher risk: >5 mg/kg/day, CKD, female sex, Asian ethnicity. This supports dose optimization and targeted SD-OCT screening.

🧪📚 Our team's scoping review of tsDMARD use in pregnancy: From 6,712 records, only 8 studies met criteria (mostly case reports; n=1–116). Evidence was available on tofacitinib, baricitinib & upadacitinib; none on apremilast.

Stenotic large vessel vasculitis is a rare and largely unknown subtype of giant cell arteritis (GCA). Retrospective study of 3,149 patients evaluated long-term outcome and prognosis of GCA with stenotic LVV Arthritis & Rheumatology acrjournals.onlinelibrary.wiley.com/doi/10.1002/...

In a nationwide cohort, spondyloarthritis diagnosis was associated with inflammatory bowel disease preceding & following its diagnosis. Findings also demonstrated temporal variability & highlighted clinical variables associated with SpA in IBD A&R doi.org/10.1002/art.... @predictibd.bsky.social

Randomised controlled trial led by @lli-1.bsky.social shows counselling combined with self-monitoring tools can help people with #RheumatoidArthritis manage their condition better. It can also improve symptoms like fatigue & mood. 🔗Link to paper: pubmed.ncbi.nlm.nih.gov/38152927/

ILD trajectories differ across IIM subsets. In a BC cohort (n=111), our team found that PmPPF occurred in 13.5%, mainly in anti-MDA5+ DM & antisynthetase syndrome, and was absent in scleromyositis. PmPPF associated with ↑ active disease, ↑ rapidly progressive ILD & ↑ transplant (20% vs 1.3%).

New population-based study (n=229,300 T2D): GLP-1RAs & SGLT2is showed no ↑ or ↓ in overall autoimmune rheumatic disease risk vs. DPP4is. But SGLT2is were linked to ~50% ↓ risk of systemic ARDs. Study led by Dr. @derinkaracabeyli.bsky.social. See infographic 👇

JointHealth™ express - #ArthritisAtHome 306 – A discussion on rheum-oncology & artificial intelligence in rheumatology. Watch now: arthritisathome.jointhealth.org?p=6743 #cancer #arthritis #AI @arthritispower.bsky.social @arthritistrainees.bsky.social @schroeder-uhn.bsky.social @achronicvoice.com

Takin hydroxychloroquine as prescribed- reduces hospitalizations snd save dollars!! - as simple as that!!

What is the impact of GLP-1RA & SGLT2i use on risk of developing autoimmune rheumatic diseases (ARD)? Data from a Canadian cohort of adults w/ type 2 diabetes showed SGLT2i use was assoc w/ lower risk of systemic ARDs, but neither GLP-1RA nor SGLT2i treatment was assoc w/ lower non-systemic ARD risk

Our new study finds that early antimalarial adherence (PDC≥0.90) in incident RA/SLE is associated with lower acute care use & costs (BC cohort, 1997–2022; n=25,247): 11% ↓ admissions (RR 0.89), 21% ↓ hosp days (RR 0.79), −$550 CAD costs. Robust to sensitivity analyses. See graphical abstract below.

JointHealth™ express - Now Launching: JointHealth™ Education – #Arthritis and #MentalHealth. Click here to begin the course: bit.ly/JointHealthE... Thank you Dr. Susan Bartlett for your help with this course! 🥰 @schroeder-uhn.bsky.social @arthritistrainees.bsky.social @arthritispower.bsky.social

New Canadian living guidelines address an important gap in cancer care: managing immune checkpoint inhibitors in patients with pre-existing inflammatory arthritis & systemic autoimmune rheumatic diseases. See GRADE-based, disease-specific recommendations in the embedded infographic.

Looking to get active with #arthritis? Yoga might be a great place to start!